Evidence map›Paper›PMID 42212273›Full record

Trial reportFrontiers in pharmacology2026

A randomized, open, two-period, cross-over, single oral dose, pharmacokinetics and bioequivalence study of vitamin K

Yan Li, Yu Wang, Lu Qi, Yinjuan Li, Wenjing Zhong, Xinghe Wang

Abstract readClinical Trial
In one paragraph

Trial report in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan Li *Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yu Wang *Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Lu QiPhase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yinjuan LiPhase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Wenjing ZhongHainan Brilliant Pharmaceutical Co., Ltd., Chengdu, China.
Xinghe WangPhase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Vitamin K Methods: This was a randomized, open-label, two-period, single-dose, crossover bioequivalence study conducted under both fasting and fed conditions, with 28 participants in each condition. Participants received 10 mg oral dose of test (T) or reference (R) drug in the first period and the opposite drug in the second period, with a 9-day washout. Blood concentrations of the E and Z isomers of VK Results: Under fasting conditions, the 90% CIs for the GMRs of C Conclusion: The VK Clinical Trial Registration: http://www.chinadrugtrials.org.cn/index.html, identifier CTR20223408; https://www.chictr.org.cn/, identifier ChiCTR2500096211.

Indexed as

bioequivalencehealthy volunteerspharmacodynamicspharmacokineticsvitamin K1 injection

Identifiers

PMID42212273
PMCPMC13213390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.